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Abstract
Background: The burden of dengue continues to increase globally, with an estimated 100 million clinically apparent
infections occurring each year. Although most dengue infections are asymptomatic, patients can present with a wide
spectrum of clinical symptoms ranging from mild febrile illness through to severe manifestations of bleeding, organ
impairment, and hypovolaemic shock due to a systemic vascular leak syndrome. Clinical diagnosis of dengue and
identification of which patients are likely to develop severe disease remain challenging. This study aims to improve
diagnosis and clinical management through approaches designed a) to differentiate between dengue and other
common febrile illness within 72 h of fever onset, and b) among patients with dengue to identify markers that are
predictive of the likelihood of evolving to a more severe disease course.
Method/Design: This is a prospective multi-centre observational study aiming to enrol 7–8000 participants aged≥
5 years presenting with a febrile illness consistent with dengue to outpatient health facilities in 8 countries across Asia
and Latin America. Patients presenting within 72 h of fever onset who do not exhibit signs of severe disease are eligible
for the study. A broad range of clinical and laboratory parameters are assessed daily for up to 6 days during the acute
illness, and also at a follow up visit 1 week later.
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Discussion: Data from this large cohort of patients, enrolled early with undifferentiated fever, will be used to develop
a practical diagnostic algorithm and a robust clinical case definition for dengue. Additionally, among patients with
confirmed dengue we aim to identify simple clinical and laboratory parameters associated with progression to a more
severe disease course. We will also investigate early virological and serological correlates of severe disease, and examine
genetic associations in this large heterogeneous cohort. In addition the results will be used to assess the new World
Health Organization classification scheme for dengue in practice, and to update the guidelines for “Integrated
Management of Childhood Illness” used in dengue-endemic countries.
Trial registration: NCT01550016. Registration Date: March 7, 2012
Keywords: Dengue, Asia, Latin America, Diagnosis, Risk prediction, Pathogenesis
Background
Dengue is an arboviral disease caused by infection with
any one of four related dengue virus (DENV) serotypes.
It is currently the most important mosquito-borne viral
pathogen affecting humans, and is emerging as a major
threat to global health. Best estimates indicate that some
3 billion people live in parts of the world where they are
at risk of infection and that around 96 million symptom-
atic episodes and approximately 20,000 deaths occur
each year [1]. As yet, neither vaccines nor specific ther-
apies are available although both areas are currently the
focus of intense research efforts.
Among symptomatic dengue cases a wide variety of
clinical manifestations are seen, ranging from mild fe-
brile illness to severe and potentially fatal disease. Only
a small proportion of patients progress to more severe
disease, typically manifesting with a transient systemic
vascular leak syndrome around the time of deferves-
cence; plasma leakage occurs, usually accompanied by
altered haemostasis and thrombocytopenia [2]. Leakage
may be profound, particularly in children, sometimes
resulting in life-threatening dengue shock syndrome
(DSS). Other severe complications, such as severe liver,
cardiac or neurological involvement, may also occur but
are less frequent. With expert supportive care mortality
rates have been reduced to very low levels, in many cen-
tres of excellence down to less than 1 % for those with
severe disease [3]. Careful observation and judicious use
of intravenous fluid therapy are crucial, with urgent
shock resuscitation required in only a small proportion
of cases. However, a major issue for clinicians treating
such patients remains the fact that clinical diagnosis of
dengue is difficult in the early febrile phase of the illness
without reliance on expensive diagnostics. Secondly pre-
diction of risk for the development of complications
such as shock due to systemic vascular leak syndrome is
currently poor. As a result very large numbers of patients
with possible dengue, potentially at risk for severe disease,
are admitted to higher level healthcare facilities in en-
demic areas primarily for observation, overburdening the
system such that the often limited local resources are not
used to maximal advantage for those patients who do
need expert care.
Clinical features and warning signs
Two major clinical syndromes, dengue fever (DF) and
dengue haemorrhagic fever (DHF), were first described
50 years ago in Thailand, with case definitions and man-
agement guidelines published by the World Health
Organization (WHO) in the 1970s [4]. However, practical
limitations with this classification system have become
increasingly apparent, and a growing body of evidence
indicates that the two syndromes are part of a continuous
spectrum of disease rather than being discrete entities
[5–8]. As a result a revised classification system has been
developed, based in part on prospectively collected data
from over 2000 patients recruited across seven endemic
countries (DENCO study), which was adopted in the re-
vised WHO dengue guidelines published in 2009 [9, 10].
The new scheme classifies the disease more simply into
dengue and severe dengue, with the hope that this will
prove more effective for triage and clinical management,
and will also improve the quality of surveillance and
epidemiological data collected globally.
Dengue and other febrile illnesses (OFI) share many
clinical features (e.g. headache, myalgia, rash), and most
countries where dengue is common also have epidemics
of illnesses such as measles, typhoid, leptospirosis and
influenza that are easily confused with dengue in the
early phase. Although a case definition for dengue fever
has been included in the WHO guidelines for many
years [11, 12], in view of the variability in clinical presen-
tation laboratory confirmation is considered desirable.
However for many endemic countries this is not a feas-
ible option, and simple and inexpensive strategies that
rely on clinical and/or readily available laboratory pa-
rameters to provide a reliable early diagnosis are needed.
Clinical warning signs suggestive of likely progression to
severe dengue are also included in the new guidelines,
but the evidence from the DENCO study in support of
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specific warning signs was limited by the small numbers
of patients who progressed to the severe category while
under observation. Thus, although warning signs are
considered a key component for early recognition of
potentially severe disease, the current evidence for any
clinical/laboratory markers is weak. Further research is
need to determine whether clinical/laboratory warning
signs with high predictive power can indeed be identi-
fied, but to do this a very large cohort of patients needs
to be assessed from the early febrile phase, in order to
capture sufficient patients who progress to more severe
disease.
Pathogenesis
Despite intensive efforts dengue disease pathogenesis
remains incompletely understood, particularly in relation
to the mechanisms responsible for the systemic vascular
leak syndrome [13]. It is clear that although all four viral
serotypes can cause fatal disease, second or subsequent
infections are much more likely to be associated with se-
vere clinical manifestations than primary infections [14,
15]. There is also evidence to suggest that severe disease
is associated with higher plasma viremia, and to impli-
cate immune response mechanisms to the virus as playing
a significant role in pathogenesis [16, 17]. However, data
on plasma viremia in primary versus secondary infections
and/or in relation to disease severity are inconsistent, and
detailed examination of viremia kinetics has been limited
to date, with the focus primarily on hospitalised patients
[18–20].
Dengue non-structural protein (NS1) is a glycoprotein
expressed by dengue-infected cells [13, 21, 22]. The avail-
ability of commercial antigen-capture assays that detect
NS1 in plasma or serum presents an opportunity for it to
be used for early and rapid dengue diagnosis. It has also
been proposed as a prognostic marker for severe disease
[23]. Numerous studies have confirmed NS1 to be highly
specific for dengue, but sensitivity has been variable
according to the serotype involved, the geographical loca-
tion, the immune status of the patient, and the day of
illness on testing [24, 25]. Since it is crucial to understand
the limitations of such tests before they can be recom-
mended for routine use in the community, large, well-
powered studies that can determine the true sensitivity
and specificity of NS1 testing in real world settings are
essential.
Dengue virus reactive IgG antibodies are also considered
to play a critical role in determining risk for severe dengue
via processes such as virus neutralisation and/or infection
enhancement [26]. However, despite their importance the
features of polyclonal sera that are associated with develop-
ment of severe dengue have not been characterised as yet.
Finally, although genetic predisposition to dengue has long
been suggested, almost every study on this topic has been
underpowered, did not consider population stratification,
and did not go on to replicate the findings in independent
patient cohorts. In the first genome-wide case–control gen-
etic association study performed in dengue, several SNPs
associated with DSS that are significant at the genome-wide
level were identified, the most striking associations being
SNPs in the MICB and PLCE1 genes [27]. Genetic variants
of MICB and PLCE1 have also been found to be associated
with less severe forms of dengue, and also dengue in infants
[28]. Validation that these SNPs are associated with a) clin-
ically apparent dengue (as distinct from DSS) in patients
from other Asian and also Latin American countries and b)
the magnitude of viremia or NS1 concentration in the early
febrile period are required.
In summary, the pathological mechanisms associated
with severe dengue remain obscure, and the crucial ques-
tion of exactly how the virus causes the serious complica-
tions observed in patients remains unanswered.
Primary objectives
The study aims to improve diagnosis and clinical man-
agement of dengue through approaches designed a) to
differentiate between dengue and other common febrile
illness within 72 h of fever onset, and b) among
patients with dengue to identify markers that are pre-
dictive of the likelihood of evolving to a more severe
disease course.
 AIM 1: To identify clinical and/or simple laboratory
parameters which differentiate between dengue and
non-dengue illness within the first 72 h of fever, with
the overall aim of developing a robust case definition
for dengue.
 AIM 2: To identify clinical and/or simple laboratory
parameters among dengue infected patients that
predict likely progression to a more severe disease
course.
 AIM 3: To identify virological correlates of severe
dengue – in particular to assess plasma viremia and
NS1 antigenemia within the first 72 h of fever in
patients with confirmed dengue.
 AIM 4: To identify early serological correlates of
severe dengue, in order to characterize differences
between severe and uncomplicated disease.
Secondary Objectives
 AIM 1: To evaluate practical application of the
original (WHO 1997) and the new dengue
classification schemes (WHO 2009) across a series
of clinical sites.
 AIM 2: To use the data to update the guidelines for
“Integrated Management of Childhood Illness” used
in dengue-endemic countries.
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Methods/Design
This is a prospective multi-centre observational study aim-
ing to enrol 7 to 8,000 patients presenting with a febrile
illness consistent with a diagnosis of dengue to outpatient
health facilities in urban centres in 8 countries across Asia
and Latin America. The study is coordinated centrally by
the Section Clinical Tropical Medicine in Heidelberg,
Germany, and the Oxford University Clinical Research Unit
(OUCRU) in Ho Chi Minh City (HCMC), Vietnam. The
countries participating in the study, and the centres coord-
inating the work locally in each country, are indicated in
Table 1. The study is being performed in accordance with
ICH-GCP guidelines, with regular oversight by a team of
independent monitors.
Study population and patient enrolment
Both adults and children (≥5 years) are eligible for enrol-
ment, and it is anticipated that the relative proportions
will reflect the expected local dengue epidemiology in
each country. Following appropriate informed consent,
subjects presenting to outpatient departments (OPD) at
the designated sites with fever for ≤ 72 h without localiz-
ing features, i.e. consistent with a possible diagnosis of
dengue, are being enrolled.
Inclusion criteria
Any patient presenting to the OPD at the participating
centres is eligible for enrolment if they meet the follow-
ing criteria:
 Age ≥ 5 years
 Fever or history of fever for ≤ 72 h
 Clinical symptoms consistent with possible dengue –
i.e. suspected dengue and/or undifferentiated fever in a
patient from a dengue endemic area
 Considered by the treating physician to be suitable for
outpatient care at the time of study enrolment – i.e. no
signs of severe disease
 Written informed consent
Exclusion criteria
 Localizing features suggesting an alternative
diagnosis, eg pneumonia, otitis etc.
 The physician judges that the patient is unlikely to
attend daily follow up - e.g. due to travelling
distance from the clinic
At each OPD a triage system has been established to dir-
ect potentially eligible subjects to a selected outpatient
room/area for consideration for enrolment, where study
staff are available to assist the regular clinic staff in patient
enrolment and collection of data. The study staff discuss
the study with all potential adult participants or, in the
case of children 5–17 years of age accompanied by a
parent/guardian, with the accompanying parent/guardian.
Study staff describe the purpose of the study, the study
procedures, possible risks/benefits, the rights and respon-
sibilities of participants, and alternatives to enrolment,
and provide a written Patient Information Sheet. If the
patient or parent/guardian agrees to participate, they are
asked to sign an Informed Consent Form, a copy of which
is then given to them to keep. If the patient or parent/
guardian is indecisive about enrolment, they are given as
much time as necessary to consider the study up until
72 h of illness has passed at which point the patient/child
is no longer eligible for the study. Children aged 12–17
are also asked to give assent to the study, after discussion
with study staff and having their questions answered. A
separate Assent Form is provided, for the child to sign
with a copy for them to keep. In addition to the proce-
dures above, illiterate signatories have the Informed
Consent/Assent Form read to them in the presence of a
witness who signs to confirm this. All Patient Information
Sheets and Consent/Assent forms are written in the local
language and use terms that are easily understandable.
Data collection instrument
A structured clinical questionnaire is completed upon
enrolment and then once daily for up to six days for all
patients in the study. This case report form (CRF) in-
cludes detailed clinical signs and symptoms, as well as
all standard laboratory results. Data collection focuses in
particular on recording the timing of onset of new signs
or symptoms, and on assessing the severity of symptoms
in a systematic way (mild/moderate/severe). The final
format was agreed by the Principal Investigators at the
participating clinical centres prior to translation into
relevant languages for local use. The CRF is supported
by a series of standard operating procedures (SOPs) de-
scribing in detail all study procedures, severity defini-
tions and methods for documentation, and all SOPs are
also presented in the appropriate local language.
Clinical evaluation
Following enrolment clinical history and examination find-
ings are recorded in the CRF, and a 3–5 ml (age-dependent)
research blood sample is obtained, together with appropri-
ate samples to measure a range of haematological and
biochemical parameters following local laboratory require-
ments (Table 2). Patients are then reviewed daily in the
OPD until fully recovered and afebrile for 24 h, or for up to
6 days from enrolment. A rapid access card is provided to
each study participant to facilitate these daily visits. Stan-
dardized clinical information is recorded and a full blood
count is performed at each visit, plus any other tests
deemed necessary by the clinic physician. On the last acute
illness visit (within approximately 24 h of defervescence) a
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Table 1 Countries/centres enrolling participants into the study
Coordinating Centre City, Country Ethics Committees Involved
Heidelberg University Hospital San Salvador, El Salvador • Comité de Ética en Investigación Clínica (CEIC), Hospital Nacional de Niños Benjamín Bloom,
San Salvador, El Salvador
Ethics Committee, Faculty of
Medicine, Heidelberg University
Fortaleza, Brazil • Comitê de Ética em Pesquisa da Universidade Estadual do Ceará (CEP-UECE), Fortaleza, Brazil
• Comissão Nacional de Ética em Pesquisa (CONEP), Brasília, Brazil
Recife, Brazil • Comitê de Ética em Pesquisa do Centro de Pesquisas Aggeu Magalhães (CEP-CPqAM)
• Comitê de Ética em Pesquisa em Seres Humanos do Instituto de Medicina IntegralProf.
Fernando Figueira (CEP-IMIP), Recife, Brazil
• Comissão Nacional de Ética em Pesquisa (CONEP), Brasília, Brazil
Rio de Janeiro, Brazil • Instituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz (Fiocruz),
Rio de Janeiro, Brazil
• Comissão Nacional de Ética em Pesquisa (CONEP), Brasília, Brazil
Maracay, Venezuela • Comité de Bioética del Instituto de Investigaciones Biomédicas de la Universidad de
Carabobo, Maracay, Venezuela
Dhaka, Bangladesh • Ethical Review Committee, International Centre for Diarrhoeal Disease Research, Dhaka,
Bangladesh
Oxford University Clinical
Research Unit – Viet Nam
Yogyakarta, Indonesia • Medical and Health Research Ethics Committee, Faculty of Medicine, Gadjah Mada University,
Yoygakarta, Indonesia
Oxford Tropical Research
Ethics Committee (OxTREC)
Siem Reap, Cambodia • Institutional Review Board, Angkor Hospital for Children, Siem Reap, Cambodia
Kuala Lumpur, Malaysia • Medical Ethics Committee, University of Malaysia Medical Center, Kuala Lumpur, Malaysia
• Medical Research and Ethics Committee, Ministry of Health, Kuala Lumpur, Malaysia
Ho Chi Minh City, Viet Nam • Ethics Committee, Children’s Hospital Number 2, Ho Chi Minh City, Viet Nam
• Ethics Committee, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
Hanoi, Viet Nam • Ethics Committee, National Hospital for Tropical Diseases, Hanoi, Viet Nam
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second sample for a biochemical profile is obtained to-
gether with a sample for serology. All patients are then
asked to attend a final follow-up visit around day 10–14 of
illness, at least one week from the last visit during the acute
illness. In addition to a clinical assessment at this time a last
blood sample is taken for convalescent serology and a full
blood count.
All management decisions throughout the acute illness
are at the discretion of the clinic physicians. Any patient
requiring hospital admission continues to be followed
daily using a similar but more detailed CRF, with the
indication(s) for admission clearly documented, and all
management interventions recorded together with the
physician’s rationale for these interventions.
Laboratory evaluation
Haematology and biochemistry profiles are performed
on standard laboratory instruments at the various par-
ticipating sites, with evidence for quality assurance and
quality control checked by study monitors at regular
intervals.
NS1 antigen detection (Platelia NS1, Biorad) and diag-
nostic serological assays (IgM and IgG Capture ELISA
Kits, Panbio, Australia) are being performed in batches
at a designated laboratory in each country, or at the
OUCRU laboratory in HCMC if in-country diagnostics
are not feasible. Proficiency panels were used to assess
the capacity of each site to perform the assays in an
appropriate manner before the study commenced. NS1
detection is attempted on all enrolment plasma samples,
while diagnostic serology is performed on acute and
convalescent plasma samples (follow-up visit specimen if
available, or final acute visit specimen if not).
Plasma viremia levels are measured in designated centres
on enrolment plasma samples by qRT-PCR using a vali-
dated assay. Samples from all sites in Vietnam, Cambodia,
Malaysia, Bangladesh, and El Salvador are being assayed at
the OUCRU laboratory in HCMC. The research labora-
tory at the Gadjah Mada University is responsible for
the Indonesian diagnostics, while specimens from the
remaining sites in Latin America will be assayed at the
FIOCRUZ Laboratories in Recife and Rio de Janeiro, or at
the Institute Pedro Kouri in Havana, Cuba. Harmonization
of assay protocols, reagents and equipment has been per-
formed to ensure equivalence between the laboratories. A
single diagnostic database is maintained in HCMC, where
data from all sites are collated and checked for errors/in-
consistencies following a formal data validation SOP.
For the detailed serological research studies, a range of
high-throughput functional and serological assays will be
considered for the measurement of DENV-specific anti-
bodies. The intention of the serological studies will be to
understand whether the quality and quantity of the anti-
DENV antibody response differs between patients with
mild versus severe clinical or laboratory outcomes.
Case definitions
Laboratory diagnosis of a dengue case will be in accordance
with current WHO criteria [9]. The diagnostic algorithm is
shown in Fig. 1. Briefly, any case with virological evidence
of dengue as shown by a positive RT-PCR assay or NS1
ELISA test, or who has IgM seroconversion between paired
specimens, is defined as having laboratory-confirmed den-
gue. A diagnosis of OFI is assigned to participants with no
laboratory evidence of acute or recent dengue. Among
participants with confirmed dengue a probable primary
infection is defined by negative IgG Capture results on both
the enrolment and follow-up samples, while a probable
secondary infection is defined by a positive IgG Capture
result in either or both the enrolment and follow-up
samples.
Data management
A customized data entry software tool was developed
consisting of a Microsoft Access database with a graph-
ical user interface which follows the layout of the paper
CRFs. An import function for laboratory results is built
into the data entry tool in order to facilitate automatic
uploads at the sites where this is technically feasible.
The laboratory section of the paper CRF as well as the
data entry software tool was adapted to site-specific
units in order to avoid conversion errors during data
entry. The data entry software is installed on designated
Table 2 Blood sample collection - schedule and volumes
Test Enrolment (≤72 h fever) Daily for up
to 6 days
Final acute visit Follow-up, Day 10-14
Research Dengue NS1Dengue IgM/GDENV PCR
Serological & virological and/or genetic
studies
3 ml EDTA for children
5 ml EDTA for adults
2 ml EDTA 2 ml EDTA
Haematology Full blood count 1 ml EDTA 1 ml EDTA 1 ml EDTA 1 ml EDTA
Biochemistry AST/ALT
Albumin
Creatine kinase
Creatinine
2 ml Lithium Heparina 2 ml Lithium Heparina
aor serum/an alternative additive according to local laboratory requirements
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computers with restricted access. Entered data is stored
locally at the site and can be edited until uploaded to a
secure server at the coordinating centre in Heidelberg.
Uploads are automatically integrated into the central
database. The data of the central server is mirrored to a
secure backup server.
Double data entry is carried out for 100 % of the first
100 patients enrolled at each site, then gradually redu-
cing to a minimum of 5 % double data entry depending
on the proportion of discrepancies between 1st and 2nd
entries. Plausibility checks as well as range checks are
built into the data entry tool, so that the data quality is
checked in real time during data entry. Once the data is
uploaded to the central server, the quality is checked again
for plausibility and missing values by pre-programmed
algorithms. The resulting query reports are relayed back
to the local sites for correction before the data is again
uploaded and processed for analysis.
Data and study materials will be stored for a minimum
of 5 years at each site after the completion of the project.
Individual SOPs will be written for continued storage or
destruction according to local requirements and the avail-
ability of facilities for long-term storage. After analysis, the
coordinating centre in Heidelberg will archive the data-
base for long-term storage.
Clinical monitoring
Independent monitoring has been integrated into the
programme of work from the outset to ensure full com-
pliance with Good Clinical Practice standards and all
regulatory requirements. Monitoring teams from the
OUCRU Clinical Trials Unit travel intermittently to all
study sites in Southeast Asia, while a team from Heidelberg
is responsible for the Latin American sites and Bangladesh.
Following a site initiation visit, the first monitoring visit
takes place after 50–100 participants have enrolled,
followed by regular visits (at least annually) depending
on recruitment rates. The monitors review study eligi-
bility and informed consent for 100 % of the enrolled
subjects. Data accuracy for all clinical information and
all routine laboratory results (haematology and bio-
chemistry) is also reviewed for 100 % of all participant
CRFs during the first 6 months of enrolment at each
site. Thereafter this percentage is maintained or de-
creased based on the error rate found during the most
recent monitoring visit. At the end of each visit, the
monitoring team meets with the site principal investi-
gator and relevant study staff to review and present any
findings, and on subsequent monitoring visits the teams
review changes made in response to previous findings/
recommendations.
Statistical methods and analysis of results
The statistical methodology to be used for the primary
objectives is summarised briefly in the following section.
Detailed analysis plans will be formulated and docu-
mented prior to commencement of particular sections of
the analysis relating to specific aims.
Sample size
We anticipate that dengue will be confirmed in ~ 50 %
of the patients enrolled in Asia and ~ 20–30 % of the
patients enrolled in Latin America. We also expect to
make a definite negative diagnosis – i.e. that the patient
NS1 positive
PCR positive
yes
IgM seroconversion in MAC 
ELISA from S1 to S2
IgM positive in MAC ELISA 
in a single tested specimen 
OR in paired specimems
No laboratory evidence of acute or recent dengue  if 
virologically and serologically negative in  paired samples with 
2nd sample collected 6 or more days after illness onset  and >2 
days after 1st sample. If samples are negative but do not meet 
these timing criteria then call “Inconclusive”
Recent  
flavivirus 
infection
OR
yes
yes
Presumptive or 
recent Dengue
NO
yes
OR
yes
NO
NO
yes
Acute flavivirus 
infection
OR
Lab Confirmed 
acute dengue
Lab Confirmed 
acute dengue
Lab Confirmed 
acute dengue
IgG seroconversion in GAC 
ELISA from S1 to S2
IgG positive in GAC ELISA in 
a single tested specimen OR
in paired specimems
Fig. 1 Diagnostic Algorithm. PCR and NS1 results are obtained from analyzing the enrolment sample while IgM and IgG results are obtained
from analyzing an acute phase sample (S1) and a follow-up/early convalescent phase sample (S2). In the presence of a clinical syndrome that
might be dengue, a positive result on any of the first 3 tests is sufficient for a diagnosis of “laboratory confirmed acute dengue”
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did not have dengue – in at least 80 % of the remaining
patients. Among hospitalised patients enrolled in previ-
ous descriptive studies in Vietnam around 5 % of cases
progressed to severe disease; there is currently no data
available for patients managed in the community but the
progression rate is likely to be lower. In this study,
among patients with confirmed dengue we will use two
definitions of more severe disease: 1) severe dengue as
defined in the new WHO 2009 classification scheme and
2) the combined endpoint of hospitalization or IV fluid
administration or severe dengue. From a total enrolment
of 7–8,000 cases we anticipate that around 3,000 dengue
cases will be included in the cohort, potentially with
100–150 patients progressing to severe disease, primarily
dengue shock syndrome. Hospitalization and/or IV fluid
administration are likely to be considerably more com-
mon but will vary according to resources available and
local clinical guidelines; however it seems plausible that
the relative effect of risk factors on outcome will be
similar across countries and regions. A dengue cohort of
this size should allow for the assessment of up to 15
candidate risk factors even for the less frequent outcome
of severe disease.
Development of a robust case definition for dengue
We will assess a broad range of clinical and labora-
tory parameters in order to develop a robust clinical
case definition for dengue; covariates assessed will in-
clude demographic information, symptoms at presen-
tation, examination findings, and readily available
laboratory parameters such as the haematocrit, white
blood cell count, lymphocyte count, platelet count
etc. as well as simple biochemical measures such as
AST, ALT, plasma albumin etc. Development of the diag-
nostic algorithm will follow standard recommendations
for clinical prediction models [29]. Logistic regression will
be the primary statistical model but we will also investi-
gate modern flexible classification algorithms such as
classification trees and random forests [30]. We anticipate
that early changes in serial haematological markers, in
particular the platelet count, white blood count and/or
lymphocyte count may facilitate diagnosis. Therefore
more complex models that include changes in marker
values between successive days will also be investigated.
The presumptive case definition for dengue versus
OFI may vary according to the background endemicity
of other diseases, and we will investigate whether strati-
fication by country or region is necessary. Potential
heterogeneity will be assessed by including a fixed con-
tinent effect and random country/site effects (mixed
effects model), and by testing for covariate-continent/
country interactions (fixed effects model) in the logistic
model [29].
The main aim for this section of the work is to develop
a dengue case definition that can be reliably used at the
primary healthcare level, but we may also be able to
suggest modifications that could be incorporated into the
algorithm if used at higher level healthcare facilities or in
middle income countries with more resources available at
the primary level. If appropriate the final model will be
simplified to a point scoring system or electronic applica-
tion for direct clinical use [31].
Prediction of risk for progression to severe dengue
Among patients with confirmed dengue we will identify
simple clinical and laboratory parameters associated with
either of the two definitions of more severe disease de-
scribed above. Heterogeneity of outcomes will be assessed
prior to pooling datasets from different countries. Classical
prognostic models depend on baseline covariates only.
However, we anticipate that early changes in serial haem-
atological markers, in particular the platelet count, white
blood count and/or lymphocyte count, or potentially in
clinical parameters may carry important additional prog-
nostic information. Thus there is a need to incorporate
longitudinal data into the prognostic models and to update
the models based on incoming data – e.g. by developing
partly conditional models or joint models of longitudinal
markers and outcome [32, 33].
Identification of early virological correlates of severe
dengue
We will test the hypothesis that viral markers associated
with development of severe dengue can be identified
within the first 3 days of fever. We will define the sensitiv-
ity, specificity, positive and negative predictive values of
NS1 detection within 3 days of fever onset for the same
severity measures as indicated above and will also explore
the use of statistical models for severity prediction.
Identification of early serological correlates of severe
dengue
We will assess a variety of antibody responses (neutraliz-
ing and enhancing titers against the 4 dengue serotypes
plus antibody titers against E, DIII, prM and NS1 of the
4 serotypes) in relation to clinical outcome, plasma
viremia and NS1 antigenemia, and will develop a model
of the serological responses seen in order to identify
correlates of severe disease.
Ethical considerations
This research project follows international standards for
the ethical conduct of research involving human subjects.
Ethical clearance has been obtained from the responsible
institutional and national boards for each participating
country (Table 1). Prior to commencing the study 3-day
workshops were arranged in each country to provide a)
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general training in research ethics and ICH-GCP and b)
specific training on the study protocol for all staff, as well
as to allow development of locally appropriate SOPs for
enrolment, daily follow-up, sample management etc. to-
gether with designated staff members. All staff involved in
the study completed the relevant training before the study
commenced at their site, and additional courses are being
provided at intervals to ensure GCP training is maintained
up to date.
Informed consent
Written informed consent is obtained from all patients
or from the parent/guardian of children, as described
above in the section on patient enrolment.
Confidentiality
Participants are assured that all information generated in
this study will remain confidential. All data (including clin-
ical, laboratory and genetic data) are stored in password-
protected databases. Participants’ names are recorded at
the time of enrolment to allow for their identification at
follow-up visits, but identifiable information is linked to
stored data or samples only by a protected Master List. This
list is not shared outside the study staff at a unique hospital,
and no identifying information is transferred between sites.
All CRFs and samples are labelled with a study identifica-
tion number only and stored in suitable secure locations.
Only persons who have signed the locally appropriate data
protection commitment form have access to the password-
protected computer where entered data is stored. After
conclusion of the project data will be removed from the
computers and stored in a safe place.
Diagnostic tests
This is a prospective observational study in which den-
gue diagnostic tests are performed on plasma samples
from suspected dengue patients. The diagnostic tests are
not performed in real time but batch tested at intervals;
thus neither the patient nor the study/attending doctors
are given the results of the tests as we intend to evaluate
their accuracy in identifying patients who progress to
severe dengue without the bias introduced by physicians
interpreting and making clinical management decisions
based on these test results. The routine diagnostic tests
performed at each site are available to the treating clini-
cians as per the local standard of care. The research
diagnostic tests are not routine in these settings and
therefore we are not altering the current standard of
care in the outpatient setting.
Genetic testing, export and storage of samples
We ask participants (or their parents/guardians) to con-
sent to having blood samples stored, to export samples,
and potentially to have genetic studies performed on the
study participants’ DNA. All stored and exported samples
are pseudonymized and linked to protected identifying
information at the study site only. No identifying data is
exported or shared. Any genetic studies performed are
exploratory and it is made clear to participants that we do
not know whether the results will be helpful in treating
patients with this disease.
Participant remuneration
We ensure that study participation imposes no cost
implications for the patient or family. All research tests
and study medical consultations are paid for by the
study, and travel costs at appropriate local rates are re-
imbursed for attendance at the daily follow-up visits. No
other financial incentives are offered.
Exclusion of children under 5 years
The sample size calculation is based on approximately
40 % of patients enrolled to the study testing positive for
dengue. In children less than 5 years, the number of
confirmed dengue infections among patients presenting
with undifferentiated fever is much lower than in the
rest of the population due to the high incidence of other
infections. By excluding children less than 5 years old,
the desired sample size can be met with a lower overall
enrolment and fewer small children being exposed to the
risks and inconvenience of participation/blood sampling.
Local health resources
Dedicated study staff are funded by the program to exe-
cute study related procedures in order to minimise the
burden of the research on local health staff and facilities.
In addition study staff help to reduce the regular workload
of clinic staff by contributing to standard care activities.
Discussion
Differentiating dengue from other common febrile ill-
nesses before complications develop is difficult. Simple
and inexpensive strategies are urgently needed to sup-
port early and accurate diagnosis, as well as to identify
patients at high risk of developing complications, in
order both to improve case management and to facilitate
appropriate use of limited resources. Evaluation of early
clinical features alongside readily available laboratory
tests in a large cohort of patients encompassing the
breadth of dengue disease encountered in endemic set-
tings is necessary to develop a robust case definition for
dengue, and could also prove to be very useful for the
development of prognostic algorithms. Similarly, charac-
terisation of the profiles of important viral and sero-
logical biomarkers in such a cohort is likely to provide
valuable information that could contribute additional in-
put into diagnostic and prognostic algorithms. Improved
strategies for early diagnosis and risk prediction would
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also enhance the conduct of clinical trials of early thera-
peutic interventions for dengue e.g. use of anti-viral or
immunomodulatory drugs. Finally preliminary evidence
indicates associations between certain genetic markers
and severe dengue; this cohort should provide a valuable
resource to investigate these genetic associations in
more detail.
Timeline
The study commenced at one site in Vietnam in October
2011 and was gradually extended to the other participating
countries such that all sites were actively recruiting by
September 2014. As of December 2015 a total of 7096
participants had been enrolled, with dengue confirmed in
2510/5996 (42 %) of the cases for which dengue diagnostics
are available at this time. Staggered close out is planned
over the coming 6 months, with all sites expected to
complete enrolment by June 2016. A formal data analysis
plan has been written, and full analysis/interpretation, dis-
semination of the findings, and report writing are scheduled
to take place by the end of 2016.
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